Merck & Co Stock Discussion

$Merck & Co(MRK.US)$I think it’s just a temp pullback, it just broke the double-bottom line as well as the recent resistence simetanously. The pullback volume is also lower. Expecting new ATH.

$Merck & Co(MRK.US)$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US)$ already has an active partnership with $Janux Therapeutics(JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US)$ in which $Merck & Co(MRK.US)$ already has a seat at the table.
$Merck & Co(MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...

$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Harmony Biosciences(HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US)$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)

$Merck & Co(MRK.US)$ 🎉
FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)
⇨ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 🫁
» CAPVAXIVE (V116) protects against most strains causing illness in adults over 50. 🛡️
»  Effective in people who've never had a pneumococcal vaccine or already have one as demonstrated in Ph3 trials.

$Merck & Co(MRK.US)$ 121 this week?

Morning Movers
Gapping up
$Chegg(CHGG.US)$ stock saw an impressive 18.01% increase after the education technology company announced a significant workforce reduction, cutting 23% of its global staff as a part of an extensive restructuring initiative.
$Merck & Co(MRK.US)$ shares experienced a 1.11% uptick following the U.S. Food and Drug Administration's approval of the pharmaceutical giant's advanced vaccine designed to protect a...

$Merck & Co(MRK.US)$
👉 Key Highlights:
📍 FDA approves Merck’s Capvaxive vaccine for pneumococcal disease.
📍 Capvaxive protects against 21 strains of pneumococcus bacteria.
📍 First pneumococcal conjugate vaccine designed specifically for adults.
📍 Targets severe pneumococcal disease, including pneumonia and meningitis.
📍 150,000 U.S. adults hospitalized annually with invasive pneumococcal disease.
📍 Merck expects rapid uptake and significa...

Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US)$ to acquire EyeBio
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Novartis AG(NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...